These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 1603471)
1. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat. Turner JH; Claringbold PG; Berger JD; Martindale AA; Glancy JR Nucl Med Commun; 1992 May; 13(5):321-9. PubMed ID: 1603471 [TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation. Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933 [TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Ricci S; Boni G; Pastina I; Genovesi D; Cianci C; Chiacchio S; Orlandini C; Grosso M; Alsharif A; Chioni A; Di Donato S; Francesca F; Selli C; Rubello D; Mariani G Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1023-30. PubMed ID: 17242920 [TBL] [Abstract][Full Text] [Related]
7. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP. Appelbaum FR; Brown PA; Sandmaier BM; Storb R; Fisher DR; Shulman HM; Graham TC; Schuening FG; Deeg HJ; Bianco JA Blood; 1992 Sep; 80(6):1608-13. PubMed ID: 1520886 [TBL] [Abstract][Full Text] [Related]
8. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117 [TBL] [Abstract][Full Text] [Related]
9. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026 [TBL] [Abstract][Full Text] [Related]
10. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021 [TBL] [Abstract][Full Text] [Related]
11. Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma. Essman SC; Lewis MR; Miller WH J Nucl Med; 2005 Dec; 46(12):2076-82. PubMed ID: 16330573 [TBL] [Abstract][Full Text] [Related]
12. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats]. Shi B; Fu Z; Lei XH Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873 [TBL] [Abstract][Full Text] [Related]
13. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. Liepe K; Runge R; Kotzerke J J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184 [TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases. Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829 [TBL] [Abstract][Full Text] [Related]
15. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases]. Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908 [TBL] [Abstract][Full Text] [Related]
16. Analysis of multiple factors related to hematologic toxicity following 153Sm-EDTMP therapy. Liu H; Zhan H; Sun D; Xu W; Ye X; Zhang H; Zhao C; Bao C; He G; Yin F Cancer Biother Radiopharm; 2007 Aug; 22(4):515-20. PubMed ID: 17803446 [TBL] [Abstract][Full Text] [Related]
17. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Macfarlane DJ; Durrant S; Bartlett ML; Allison R; Morton AJ Nucl Med Commun; 2002 Nov; 23(11):1099-106. PubMed ID: 12411839 [TBL] [Abstract][Full Text] [Related]
18. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. Bayouth JE; Macey DJ; Kasi LP; Fossella FV J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819 [TBL] [Abstract][Full Text] [Related]
19. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Liepe K; Kotzerke J Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384 [TBL] [Abstract][Full Text] [Related]
20. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. Brenner W; Kampen WU; Kampen AM; Henze E J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]